During September 5th -8th, the Society for the Study of Dermatovenereologic and Allergic Diseases (S.S.D.A.D.) carried out its 2nd Panhellenic Conference at Zappeion Aegli, Athens, under the title: “Dermatological diseases 2019: Past, present and future”. IASIS PHARMA was present, participating dynamically for once more in the field of Dermatology.
Dermatologists who attended the Conference had the chance to visit IASIS PHARMA exhibition stand, thus getting informed about three of its major Dermatological products.
Ιsotroin®, isotretinoin, a retinoid for the treatment of acne, is the only product of its kind in the Greek market available in 3 strengths: soft caps of 10mg, 20mg and 40mg, helping the dermatologist to ideally set the patient’s dosage.
Special interest was shown for Modiwart®, with imiquimod as its active ingredient. Modiwart® is an innovative immunomodulator, with the following indications: external genital warts and anogenital (acuminate warts) in adults, small superficial basal cell carcinomas (sBCC) and clinically typical actinic keratoses (AKs). Modiwart® is distributed in the form of a cream for topical use in 12 sachets package. Each sachet contains 12,5 mg imiquimod in 250 mg cream (5%).
Last but not least Combi® was also displayed· a combination of miconazole + fluprednidene in the form of cream with excellent texture and the advantage of the 50g pack.